Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06339190 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis

Study acronym: NAVAIDD
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 2 months later Dec 2025 → Mar 2027
See other at-risk trials from Monash University

Record History

  1. Primary completion pushed from Dec 2025 to Mar 2027 Secondary endpoints: details revised at 2 of 3 entries · Collaborators: 7 to 6 · Publications: details revised at 1 of 1 entry · 1 more Show 4 more changesShow less
    • Secondary endpoints: details revised at 2 of 3 entries
    • Collaborators: 7 to 6
    • Publications: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 4 words
  2. Primary endpoint revised Eligibility criteria expanded, about 6 wordsv2 Show 1 more changeShow less
    • Eligibility criteria expanded, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Monash University
29 trials monitored
See 3 trials at risk
Dementia
920 trials monitored
See 46 trials at risk
This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure levels of a brain protein, Neurofilament light chain (Nfl), and assess changes in language using speech tests. Participants will have a single blood test and speech test, and will be followed up at 12-months to complete questionnaires and cognitive scales over the phone. The speech test will also be completed again at 12-months. Individuals at risk of a genetic dementia syndrome will be eligible to complete optional genetic testing involving an 'at home' saliva sample.
Trial Details
NCT Number NCT06339190
Lead Sponsor Monash University
Collaborators: Eastern Health, University of Melbourne, Wake Forest University, Deakin University, The Florey Institute of Neuroscience and Mental Health, Redenlab
Conditions Neurodegenerative Diseases, Dementia
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov